Escalon Medical Corp (ESMC) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Escalon Medical Corp $0.31, price $0.17, upside +82.4%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Escalon Medical Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0533 – $0.4800 · fair‑value band $0.2300 – $0.3900 · the $0.1700 price screens below the $0.3100 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Escalon Medical in your weekly email
Every Wednesday you see whether Escalon Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Escalon Medical Corp. engages in the development, manufacturing, marketing, and distribution of medical devices and pharmaceuticals for ophthalmic applications in the United States and internationally.
Show more
Escalon Medical Corp. engages in the development, manufacturing, marketing, and distribution of medical devices and pharmaceuticals for ophthalmic applications in the United States and internationally. It offers A-Scan, which provides information about the internal structure of the eye; B-Scan, a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque; UBM, a high frequency/high resolution ultrasound device, which provides detailed information about the anterior segment of the eye; and Pachymeter that measures the thickness of cornea. The company also provides Ispan Intraocular Gases, such as C3F8 and SF6 that are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; and AXIS Image management system for managing ophthalmic diagnostic images through the web browser from various devices. In addition, it markets disposable surgical packs used in vitreoretinal surgery, including packs that aid surgeons in the process of injecting and extracting silicone oil. Further, the company engages in the manufacturing and distribution of patented disposable universal gas kit, which delivers the gas from the canister to the patient. It sells its products to medical institutions through independent sales representatives, network of distributors, and internal sales employees. The company was incorporated in 1987 and is based in Wayne, Pennsylvania.
Stock analysis
Escalon Medical Corp (ESMC) currently trades at $0.1700, while our model-based Fair Value estimate is $0.3100, implying the stock looks roughly 45.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.4700 per share, and 20 of the 22 models we run sit above the $0.1700 price.
Bear case: the Earnings-Based group reads lowest at $0.1200, and 2 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.2300 (bear) to $0.3900 (bull), the price of $0.1700 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Escalon Medical Corp reported revenue of $12.0M in FY2025 versus $10.5M in FY2021, a compound +3.6%/yr. Reported net income was $106K in FY2025.
Key figures
Market cap $1.3M · P/E ratio 1.4 · P/S ratio 0.01 · EPS (TTM) $0.1200 · Net margin 0.9% · Return on equity 57.5% · Return on assets (EBIT) 0.0% · Operating margin −16.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 82%, ESMC screens cheaper than that median.
Fair Value models
Bear $0.2300Fair Value $0.3100Bull $0.3900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.1200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: −0.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−23.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−9% → 1%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−35.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −37.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+82% · Top 25%
Profitability
Return on equity (TTM)57% · Top 25%
Return on assets−9% · Below median
Net margin (TTM)16% · Top 25%
Operating margin (TTM)−16% · Bottom 25%
Growth and dividend
Revenue growth−25% · Bottom 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Escalon Medical Corp Fair Value". https://www.fairvalue-calculator.com/stock/ESMC
Frequently asked questions
Is Escalon Medical Corp (ESMC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.3100 versus a price of $0.1700, about +82% upside (undervalued).
What is the fair value of ESMC?
Our model-based fair value for Escalon Medical Corp is $0.3100 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.1700.
What is the quality score of ESMC?
Escalon Medical Corp has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Escalon Medical Corp (ESMC)?
Our model-based price target is the fair value of $0.3100 (as of Sep 23, 2026) from 22 valuation models. Cautious scenario $0.2300, optimistic scenario $0.3900. It is a calculation from audited fundamentals, not an analyst target.
What is the Escalon Medical Corp stock forecast for 2026?
Our models put fair value at $0.3100, about +82% upside versus a price of $0.1700 (undervalued). Cautious scenario $0.2300, optimistic scenario $0.3900. The calculation is refreshed regularly with new filings.
What is the revenue of Escalon Medical Corp (ESMC)?
Escalon Medical Corp reported trailing-twelve-month revenue of about $11.4M (latest available figure, as of Sep 23, 2026).
What growth is priced into Escalon Medical Corp (ESMC)?
For today's price to be fair in a discounted-cash-flow model, Escalon Medical Corp would have to grow free cash flow by -35.8 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of ESMC use?
Our models discount Escalon Medical Corp at 8.5 %: a base by market capitalisation (nano), damped by beta 0.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Escalon Medical Corp that is -35.8 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Escalon Medical Corp (ESMC) delivered so far?
Over the past 5 years revenue at Escalon Medical Corp grew +5.1 % a year. The price currently implies -35.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Escalon Medical Corp (ESMC) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Escalon Medical Corp (-35.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Escalon Medical Corp (ESMC)?
The free-cash-flow yield on the price is 29.89 %: that much free cash flow Escalon Medical Corp produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Escalon Medical Corp (ESMC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Escalon Medical Corp it is $0.3100 per share (as of Sep 23, 2026), against a price of $0.1700. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Escalon Medical Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ESMC trades below its calculated fair value: price $0.1700, fair value $0.3100, a gap of about +82% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ESMC?
No. The price is what the market pays today ($0.1700); the fair value is what the company's own numbers justify ($0.3100). For Escalon Medical Corp the two are $0.1400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Escalon Medical Corp worth?
The market values Escalon Medical Corp at about $1.3M (market capitalisation, as of Sep 23, 2026). Per share that is $0.1700; our models calculate a fair value of $0.3100 per share.
What do the bullish and bearish scenarios say about ESMC?
Our models span a range for Escalon Medical Corp: cautious scenario $0.2300, base $0.3100, optimistic $0.3900 per share (as of Sep 23, 2026, price $0.1700). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ESMC?
Escalon Medical Corp trades at a price-to-earnings ratio of 1.4 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.3100 is built from several models across several years. Other multiples: PEG 2.1, P/B 0.7, P/S 0.1.
What is the PEG ratio of ESMC?
The PEG ratio of Escalon Medical Corp is 2.07 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Escalon Medical Corp (ESMC)?
Balance-sheet figures for Escalon Medical Corp (as of Sep 23, 2026): return on equity 57.5%, debt of 0.12 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is ESMC from its 52-week high?
Escalon Medical Corp trades at $0.1700, about 51% below its 52-week high of $0.3500 and 42% above the low of $0.1200 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3100 is for.
Which stocks are comparable to Escalon Medical Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Escalon Medical Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.1700, calculated fair value $0.3100 (+82%), Quality Score 62/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ESMC calculated?
We run Escalon Medical Corp through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Escalon Medical Corp currently trades 82 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Escalon Medical Corp (ESMC)?
The closing price on Sep 23, 2026 was $0.1700. Our model-based fair value is $0.3100, about +82% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Escalon Medical Corp right now?
The price is below even our cautious bear case ($0.2300). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Escalon Medical Corp
How large is the market capitalisation of Escalon Medical Corp (ESMC)?
The market capitalisation of Escalon Medical Corp is $1.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Escalon Medical Corp (ESMC)?
The price-to-sales ratio of Escalon Medical Corp is 0.01 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Escalon Medical Corp (ESMC)?
Earnings per share at Escalon Medical Corp are $0.1200 (price ÷ EPS = P/E 1.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Escalon Medical Corp (ESMC)?
The net margin of Escalon Medical Corp is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Escalon Medical Corp (ESMC)?
The return on equity (ROE) of Escalon Medical Corp is 57.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Escalon Medical Corp (ESMC)?
On an EBIT basis the return on assets of Escalon Medical Corp is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Escalon Medical Corp (ESMC)?
The operating margin of Escalon Medical Corp is −16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Escalon Medical Corp (ESMC)?
Revenue at Escalon Medical Corp is growing −24.9% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Escalon Medical Corp (ESMC)?
Earnings per share at Escalon Medical Corp are growing +776% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Escalon Medical Corp in the live analysis
One click puts Escalon Medical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026